Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin
ClinicalTrials.gov · NCT07621419 · Registry updated: 2026-06-02
- Condition / research focus
- Diabetes Mellitus
- Sponsor
- Hospital Italiano de Buenos Aires
- Countries with listed sites
- Argentina
- Registry dates and results
- Start: 2025-08-04. Completion: 2028-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- semaglutide (drug)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Hospital Italiano de Buenos AiresBuenos Aires, Buenos Aires, Argentina